Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, double-blind, placebo-controlled, first-in-human, single-ascending dose trial of APG990 in healthy volunteers

Next Previous
Search
Trial Profile

A Phase 1, double-blind, placebo-controlled, first-in-human, single-ascending dose trial of APG990 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG 990 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; First in man; Pharmacokinetics

    • Most Recent Events

    • 03 Mar 2025 According to an Apogee Therapeutics media release, PK data supported the possibility of every three- and six-month maintenance dosing of APG990 with as little as 50 mg, which when considered with APG279 (APG777 + APG990) coformulation data, provides the potential for dosing the combination two to four times per year with a single 2 mL coformulated injection.
    • 03 Mar 2025 According to an Apogee Therapeutics media release, company announced live webcast of the APG990 interim Phase 1 results will begin today at 8:30 a.m. ET.
    • 03 Mar 2025 Interim results presented in an Apogee Therapeutics media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top